EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis

Gianvito Masi iD, Minh C Pham iD, Tabitha Karatz, Sangwook Oh iD, Aimee S Payne iD, Richard J Nowak iD, James F Howard iD, Jeffrey T Guptill, Vern C Juel, Kevin C O'Connor iD

Annals of Clinical and Translational Neurology · 2023

DOI: 10.1002/acn3.51761 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2023. Verfasst von Gianvito Masi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunobiology, Yale School of Medicine, New Haven, Connecticut, 06511, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Myasthenia Gravis. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, NIAID NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To compare the immunopathology of immune checkpoint inhibitor‐induced myasthenia gravis (ICI‐MG) and idiopathic MG, we profiled the respective AChR autoantibody pathogenic properties. Of three ICI‐MG patients with AChR autoantibodies, only one showed complement activation and modulation/blocking potency, resembling idiopathic MG. In contrast, AChR autoantibody‐mediated effector functions were not detected in the other two patients, questioning the role of their AChR autoantibodies as key mediators of pathology. The contrasting properties of AChR autoantibodies in these cases challenge the accuracy of serological testing in establishing definite ICI‐MG diagnoses and underscore the importance of a thorough clinical assessment when evaluating ICI‐related adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsMyasthenia GravisHumansReceptors, CholinergicAutoantibodiesComplement Activation

Substanzen

Immune Checkpoint InhibitorsReceptors, CholinergicAutoantibodies

Autor:innen und Institutionen

  • Department of Immunobiology, Yale School of Medicine, New Haven, Connecticut, 06511, USA.
  • Department of Neurology, Yale School of Medicine, New Haven, Connecticut, 06511, USA.
  • Neuromuscular Division, Department of Neurology, Duke University Medical Center, Durham, North Carolina, 27710, USA.
  • Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA.
  • Department of Neurology, The University of North Carolina at Chapel Hill, CB#7025, Houpt Building, 170 Manning Drive, Chapel Hill, North Carolina, 27599-7025, USA.

ORCID-Profile: Gianvito Masi, Minh C Pham, Sangwook Oh, Aimee S Payne, Richard J Nowak, James F Howard, Kevin C O'Connor

Förderung

  • NCATS NIH HHS
  • NIAID NIH HHS
  • NINDS NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Masi, G., Pham, M. C., Karatz, T., Oh, S., Payne, A. S., Nowak, R. J., Howard, J. F., Guptill, J. T., Juel, V. C., & O'Connor, K. C. (2023). Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.51761

Vancouver

Masi G, Pham MC, Karatz T, Oh S, Payne AS, Nowak RJ, et al. Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis. Annals of Clinical and Translational Neurology. 2023. doi:10.1002/acn3.51761

BibTeX
@article{Masi2023,
  author = {Masi, Gianvito and Pham, Minh C and Karatz, Tabitha and Oh, Sangwook and Payne, Aimee S and Nowak, Richard J and Howard, James F and Guptill, Jeffrey T and Juel, Vern C and O'Connor, Kevin C},
  title = {Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2023},
  doi = {10.1002/acn3.51761}
}
Kostenlos starten →